Latest News on Lupin
Showing of 0 - 10 from 90 results
Lupin - Total results - 90
Feb 06, 2019
Lupin reports Rs 152 cr loss in Q3 on one-time provisioning for litigation expenses; income from operations riseOn 12 December, 2018, the General Court of the European Union delivered its judgment concerning Lupin's appeal against the European Commission's 2014 decision in a litigation related to Perindopril.
Dec 10, 2018
Lupin gets Establishment Inspection Report from USFDA for Pithampur facility unit; stock falls 1.88%Drug firm Lupin on Monday said it has received an Establishment Inspection Report (EIR) from the US health regulator for a unit of its Pithampur facility in Madhya Pradesh.
Nov 27, 2018
Lupin gets observation in establishment inspection report from USFDA for Tarapur facilityShares of Lupin were trading at Rs 854.00 per scrip on the BSE, up 1.09 percent from its previous close.
Aug 24, 2018
Lupin gets establishment inspection report from USFDA for its Nagpur facilityEarlier in May, in a regulatory filing Lupin had said that the US health regulator had completed inspection of the Nagpur facility without making any observations.
Aug 22, 2018
Lupin recalls over 11,000 bottles of hypertension drug in US marketLupin's US arm is recalling 11,706 bottles of Lisinopril tablets, used for treating hypertension, from the American market, USFDA said.
Aug 08, 2018
Lupin June quarter net profit dips 43% to Rs 203 cr, hit by drop in sales in US and Japan"The first quarter of FY2019 has been subdued, primarily on account of the US and Japan," Lupin Ltd Managing Director Nilesh Gupta said in a statement.
Aug 06, 2018
Q1 results, global cues, crude prices, monsoon session of Parliament to affect affect markets' moves this weekMarket analysts opined that crude oil prices and developments in the monsoon session of parliament will also affect the markets' movement.
Jun 25, 2018
Lupin to launch nearly 30 products in US market this fiscal, says managing director Nilesh GuptaLupin currently has 162 abbreviated new drug applications (ANDAs) pending approval with the US Food and Drug Administration (USFDA)
May 15, 2018
Lupin posts Q4 net loss of Rs 783 cr as company hit by one time impairment on Gavis acquisitionDrug major Lupin on Tuesday reported a consolidated net loss of Rs 783.54 crore for the quarter ended March 31, 2018, hit by one time impairment on the Gavis acquisition and other liabilities related to the US operations
Nov 21, 2017
Sensex, Nifty close high for fourth day in a row on strong global cues; pharma stocks in demandAccording to market observers, the key indices discarded the previous day's lacklustre performance to trade with substantial gains although some gains were capped as investors booked profits in banking and realty stocks